(P118) REal-World Impact of Once-Weekly Injectable Semaglutide on GLycemic Control and Weight Outcomes Based on Highest Dose Received and Persistence With Treatment in Type 2 DiAbeTEs (RELATE – OW Injectable Semaglutide)

Saturday, August 5, 2023

11:00 AM – 1:00 PM CT

Has Audio

Primary Presenter(s)

Aaron A. King, MD (he/him/his)

PHysician
MedFirst at the Quarry
San Antonio, Texas, United States

Co-Presenter(s)

James Amamoo (he/him/his)

Evidence Generation Manager
Novo Nordisk
Plainsboro, New Jersey, United States

This poster presents the results from a real-world database study that assessed the impact of the once-weekly injectable formulation of semaglutide type 2 diabetes mellitus (sema OW T2D) on HbA1c and weight outcomes from baseline to the end of a 12-month follow-up period, based on the highest dose received and persistence with treatment over the follow-up period.